Who are Adcetris's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Halaven, Jevtana Kit, Taxol, Taxol, Trastuzuma, Polatuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brentuximab-vedotin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Adcetris — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adcetris (brentuximab-vedotin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD30-directed Immunoconjugate [EPC]. Area: Oncology.

marketed CD30-directed Immunoconjugate [EPC] Tubulin beta Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Adcetris (brentuximab-vedotin) — Pfizer. Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adcetris TARGET	brentuximab-vedotin	Pfizer	marketed	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Trastuzuma	Trastuzuma	Fudan University	marketed		Receptor tyrosine-protein kinase erbB-2, Tubulin beta
Polatuzumab	Polatuzumab	National Cancer Institute (NCI)	marketed		B-cell antigen receptor complex-associated protein beta chain, Tubulin beta

Recent regulatory actions (last 90 days)

2026-03-18 — Polatuzumab · FDA · approved · US · National Cancer Institute (NCI)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 7758891*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-09-04 — Taxol · 9393318*PED · Compound · US
2032-09-04 — Taxol · 9597409*PED · Compound · US
2032-09-04 — Taxol · 9393318*PED · US
2032-09-04 — Taxol · 9597409*PED · US
2034-01-12 — Taxol · 9511046 · US
2034-01-12 — Taxol · 9511046 · Method of Use · US
2034-07-12 — Taxol · 9511046*PED · US

Sponsor landscape (CD30-directed Immunoconjugate [EPC] class)

· 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adcetris — Competitive Intelligence Brief. https://druglandscape.com/ci/brentuximab-vedotin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab